Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Linking severity of FASD symptoms to specific levels of fetal ethanol exposure; testing a new potential biomarker of fetal alcohol exposure, ethylglucuoronide (EtG)
FY 2010-11
Summary
Fetal Alcohol Spectrum Disorder (FASD) affects approximately 9.1/1000 live births, making it one of the leading preventable causes of mental disability in North America. However, drinking during pregnancy is severely underreported, as pregnant women who drink are often faced with guilt, embarrassment, and legitimate fears of child apprehension. Therefore, the development and refinement of objective measures of fetal ethanol exposure is critical to identifying at-risk neonates.
Fatty Acid Ethyl Esters (FAEEs) are byproducts of ethanol metabolism, which can be found in the meconium of neonates exposed to ethanol in utero. FAEE assays can distinguish fetal exposure from maternal exposure, since the transfer of FAEEs from mother to fetus is prohibited by the placental barrier. Therefore, FAEEs are ideal biomarkers of the degree of cumulative fetal ethanol exposure from the 12th week of pregnancy to term. Ethylglucuronide (EtG) is another metabolite of ethanol, also found in the meconium of neonates exposed to maternal drinking. However, as the handling of EtG by the placenta is currently unknown, its ability to accurately reflect fetal ethanol exposure is still unclear.
This project has three aims. The first is to observe how accurately neonatal levels of FAEEs can predict the severity of cognitive, language, and motor deficits at 3 months and 12-18 months of age. The second is to observe how an open (not anonymous) FAEE study is received by pregnant women with a history of alcohol use. The third is to test the placental handling of EtG in vitro in order to determine its efficacy as a biomarker of true fetal exposure.
Our research will not only identify new biomarkers, but will also enhance the clinical utility of existing biomarkers by mapping unique FASD clinical profiles to specific exposure levels. This will help shape early childhood interventions, which have already shown promise at attenuating FASD-related disability.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
227226
Name
Finkelberg Laura
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Clinical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Linking severity of FASD symptoms to specific levels of fetal ethanol exposure; testing a new potential biomarker of fetal alcohol exposure, ethylglucuoronide (EtG)
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ethylglucuronide; Fatty Acid Ethyl Esters; Fetal Alcohol Spectrum Disorder; Gas Chromatography; In Vitro Placental Perfusion; Mass Spectrometry; Meconium Testing; Neurodevelopment; Solid-Phase Microextraction; Transplacental Pharmacology
Abstract
Fetal Alcohol Spectrum Disorder (FASD) affects approximately 9.1/1000 live births, making it one of the leading preventable causes of mental disability in North America. However, drinking during pregnancy is severely underreported, as pregnant women who drink are often faced with guilt, embarrassment, and legitimate fears of child apprehension. Therefore, the development and refinement of objective measures of fetal ethanol exposure is critical to identifying at-risk neonates.
Fatty Acid Ethyl Esters (FAEEs) are byproducts of ethanol metabolism, which can be found in the meconium of neonates exposed to ethanol in utero. FAEE assays can distinguish fetal exposure from maternal exposure, since the transfer of FAEEs from mother to fetus is prohibited by the placental barrier. Therefore, FAEEs are ideal biomarkers of the degree of cumulative fetal ethanol exposure from the 12th week of pregnancy to term. Ethylglucuronide (EtG) is another metabolite of ethanol, also found in the meconium of neonates exposed to maternal drinking. However, as the handling of EtG by the placenta is currently unknown, its ability to accurately reflect fetal ethanol exposure is still unclear.
This project has three aims. The first is to observe how accurately neonatal levels of FAEEs can predict the severity of cognitive, language, and motor deficits at 3 months and 12-18 months of age. The second is to observe how an open (not anonymous) FAEE study is received by pregnant women with a history of alcohol use. The third is to test the placental handling of EtG in vitro in order to determine its efficacy as a biomarker of true fetal exposure.
Our research will not only identify new biomarkers, but will also enhance the clinical utility of existing biomarkers by mapping unique FASD clinical profiles to specific exposure levels. This will help shape early childhood interventions, which have already shown promise at attenuating FASD-related disability.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Finkelberg, Laura
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~